(Reuters) - Neurocrine Biosciences Inc said a lower dose of its experimental drug to treat a rare movement disorder did not meet the main goal of a mid-stage clinical study, sending its shares down 32 percent in after-market trade.
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/_aINMiSjuA8/story01.htm
phlebotomy school school phlebotomy phlebotomist school
No comments:
Post a Comment